Hormonal
GLP-1 receptor agonists (specifically semaglutide 2.4 mg/week and liraglutide 3.0 mg/day) produce significant weight loss in adults with obesity (BMI ≥27 or ≥30) when combined with lifestyle modifications, outperforming placebo and many other pharmacotherapies.
If you have obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities, GLP-1 agonists like semaglutide (2.4 mg weekly) or liraglutide (3.0 mg daily) are highly effective for weight loss when combined with diet and exercise. Semaglutide showed an average loss of 15.3 kg over 68 weeks in trials. Expect mild, temporary gastrointestinal side effects, but these rarely require stopping treatment. Oral options exist for those averse to injections.
In conclusion, it was observed that in the semaglutide group, participants were more likely to lose 5% to 20% or more of baseline body weight at week 68 than those receiving a placebo. Change in body weight from baseline to week 68 was -15.3 kg in the semaglutide group compared to -2.6 kg in the placebo group... Liraglutide together with lifestyle changes resulted in weight loss of 8.4 ± 7.3 kg compared to 2.8 ± 6.5 kg in the placebo group over these weeks.
Why this rating
Based on multiple Phase 3 randomized controlled trials (STEP, SCALE) and meta-analyses cited in the review.
Source
Use of GLP-1 analogs in the treatment of obesity: an integrative and systematic review
Giulia Biagi Furlan et al. · International Journal of Nutrology · 2023
DOI 10.54448/ijn23105
More from this paper
- GLP-1 receptor agonists (exenatide, liraglutide) are effective for weight loss in patients with schizophrenia who are gaining weight due to antipsychotic medications (clozapine/olanzapine).Moderate
- GLP-1 receptor agonists (Liraglutide, Semaglutide) are effective and safe for treating obesity in children and adolescents, with FDA approval for Liraglutide in this population.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →